Soligenix, Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest

Soligenix, Inc. (NASDAQ:SNGX) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 106,400 shares, a decrease of 12.1% from the January 31st total of 121,000 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average daily volume of 220,800 shares, the short-interest ratio is currently 0.5 days.

Soligenix Price Performance

Shares of NASDAQ SNGX opened at $2.37 on Friday. Soligenix has a one year low of $1.83 and a one year high of $14.92. The business’s fifty day moving average price is $2.53 and its 200-day moving average price is $3.25. The stock has a market capitalization of $5.95 million, a PE ratio of -0.31 and a beta of 2.03.

Institutional Trading of Soligenix

An institutional investor recently raised its position in Soligenix stock. Geode Capital Management LLC boosted its holdings in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the quarter. Geode Capital Management LLC owned 1.04% of Soligenix worth $71,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.